Skip to main content

Table 5 ICER of goserelin vs. chemotherapy in the adjuvant treatment of breast cancer

From: Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer

 

ΣQALY

ΣCost

ICERa

Goserelin vs. Chemotherapy

 

SG

VS

BSA 1.5 m2

BSA 1.8 m2

SG

VS

     

BSA 1.5 m2

BSA 1.8 m2

BSA 1.5 m2

BSA 1.8 m2

Goserelin

8.81

8.78

5,532

     

Chemotherapy

        

   CMF

6.83

7.14

1,789

1,792

1,891

1,887

2,283

2,279

   FEC

6.83

7.14

3,606

3,610

974

971

1,176

1,172

   TE

6.83

7.14

12,453

13,785

-3,495

-4,168

-4,220

-5,032

   TEC

6.83

7.14

12,517

13,849

-3,528

-4,200

-4,259

-5,071

  1. aICER = (cost goserelin - cost chemothreapy )/(QALY goserelin - QALY chemothre )
  2. BSA, body surface area; CMF, (cyclophosphamide, methotrexate, 5-fluorouracil); FEC, (5-fluorouracil, epirubicin, cyclophosphamide); TE (docetaxel, epirubicin); TEC, (docetaxel, epirubicin, cyclophosphamide)
  3. Cost in US dollars